Jubilant Augments Clinsys Clinical Research through acquisition of TrialStat ClinicalAnalytics
Jubilant Organosys Ltd. announced today that its subsidiary Clinsys Clinical Research, Inc., New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics from TrialStat for a purchase consideration of CAD 750,000.
Jubilant augments Clinsys Clinical Research® through acquisition of TrialStat ClinicalAnalytics®, an EDC platform
Jubilant Organosys Ltd. announced today that its subsidiary Clinsys Clinical Research, Inc.®, New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics® from TrialStat® for a purchase consideration of CAD 750,000.
TrialStat ClinicalAnalytics (TrialStat CA) is a Web-based electronic data capture (EDC) solution currently used by a wide range of pharmaceutical and CRO customers worldwide. TrialStat CA is the industry’s first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively.
Clinsys extensive global resources will enable TrialStat to continue its proven record of growth, customer service and product innovation. This agreement will give TrialStat’s existing CRO and biopharmaceutical customer base a broader scope of services.
“The Company had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally” said David E. Williams, Chief Executive Officer of Clinsys.
Commenting on the acquisition,Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd., said,“The addition of the TrialStat CA and its proven EDC offering will allow Clinsys to continue to expand its integrated solutions for pharmaceutical, biotechnology and medical device organizations. This acquisition is an excellent fit and addresses the industry’s continuously evolving requirements in EDC.”
About Jubilant Organosys
Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The Company has a presence across the pharmaceutical value chain for products and services that include exclusive synthesis arrangements, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) radiopharmaceuticals, Integrated drug discovery solutions, medicinal chemistry services, clinical research services, dosage forms and Health Care.
For more information visit: www.jubl.com
About Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc., is a therapeutically focused global contract research organization that provides pharmaceutical, biotechnology and medical device companies with a full range of Phase I-IV clinical research services, including clinical development, study start-up, clinical operations, biostatistics, data management, quality assurance, regulatory affairs, pharmacovigilance, medical writing, clinical pharmacology & pathology, and functional outsourcing services.
Clinsys is a Jubilant Organosys company headquartered in Bedminster, New Jersey, with operations in Raleigh, North Carolina; Philadelphia, Pennsylvania; and Düsseldorf, Germany. Clinsys Clinical Research, Ltd., with offices in Noida and Bangalore, India. Clinsys employs 400 people globally.
For more information, visit www.clinsys.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
